{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319689720192.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1158/1078-0432.ccr-05-0120"}},{"identifier":{"@type":"URI","@value":"https://aacrjournals.org/clincancerres/article-pdf/11/11/4160/1958221/4160-4167.pdf"}},{"identifier":{"@type":"PMID","@value":"15930352"}},{"identifier":{"@type":"NAID","@value":"30018691145"}}],"dc:title":[{"@value":"Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Purpose: To investigate the safety and the immunologic and clinical responses of dendritic cell therapy for patients with recurrent malignant glioma.</jats:p><jats:p>Experimental Design: Twenty-four patients with recurrent malignant glioma (6 grade 3 and 18 grade 4 patients) were evaluated in a phase I/II clinical study of dendritic cell therapy. All patients were resistant to the standard maximum therapy. The patient's peripheral blood dendritic cells were generated with granulocyte macrophage colony-stimulating factor, plus interleukin 4 with or without OK-432, and pulsed with an autologous tumor lysate. Dendritic cells were injected intradermally, or both intratumorally and intradermally every 3 weeks.</jats:p><jats:p>Results: The protocols were well tolerated with only local redness and swelling at the injection site in several cases. Clinical responses were as follows: 1 patient with partial response, 3 patients with minor response, 10 patients with stable disease, and 10 patients with progressive disease. The patients whose dendritic cells were matured with OK-432 had longer survival times than the dendritic cells from patients without OK-432 maturation. The patients with both intratumoral and intradermal administrations had a longer survival time than the patients with intradermal administration only. Increased ELISPOT and delayed-type hypersensitivity responses after vaccination could provide good laboratory markers to predict the clinical outcome of patients receiving dendritic cell vaccination. The overall survival of patients with grade 4 glioma was 480 days, which was significantly better than that in the control group.</jats:p><jats:p>Conclusions: This study showed the safety and clinical response of autologous tumor lysate-pulsed dendritic cell therapy for patients with malignant glioma. Dendritic cell therapy is recommended for further clinical studies in malignant glioma patients.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319689720067","@type":"Researcher","foaf:name":[{"@value":"Ryuya Yamanaka"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720196","@type":"Researcher","foaf:name":[{"@value":"Junpei Homma"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720066","@type":"Researcher","foaf:name":[{"@value":"Naoki Yajima"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720192","@type":"Researcher","foaf:name":[{"@value":"Naoto Tsuchiya"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720064","@type":"Researcher","foaf:name":[{"@value":"Masakazu Sano"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720195","@type":"Researcher","foaf:name":[{"@value":"Tsutomu Kobayashi"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720193","@type":"Researcher","foaf:name":[{"@value":"Seiichi Yoshida"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720065","@type":"Researcher","foaf:name":[{"@value":"Takashi Abe"}],"jpcoar:affiliationName":[{"@value":"2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720198","@type":"Researcher","foaf:name":[{"@value":"Miwako Narita"}],"jpcoar:affiliationName":[{"@value":"2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720194","@type":"Researcher","foaf:name":[{"@value":"Masuhiro Takahashi"}],"jpcoar:affiliationName":[{"@value":"2Department of Hematology, Niigata University School of Medicine, Niigata University, Niigata, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319689720197","@type":"Researcher","foaf:name":[{"@value":"Ryuichi Tanaka"}],"jpcoar:affiliationName":[{"@value":"1Department of Neurosurgery, Brain Research Institute and"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10780432"},{"@type":"EISSN","@value":"15573265"}],"prism:publicationName":[{"@value":"Clinical Cancer Research"}],"dc:publisher":[{"@value":"American Association for Cancer Research (AACR)"}],"prism:publicationDate":"2005-06-01","prism:volume":"11","prism:number":"11","prism:startingPage":"4160","prism:endingPage":"4167"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"https://aacrjournals.org/clincancerres/article-pdf/11/11/4160/1958221/4160-4167.pdf"}],"createdAt":"2005-09-21","modifiedAt":"2023-05-04","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Injections,%20Intradermal","dc:title":"Injections, Intradermal"},{"@id":"https://cir.nii.ac.jp/all?q=Dendritic%20Cells","dc:title":"Dendritic Cells"},{"@id":"https://cir.nii.ac.jp/all?q=Glioma","dc:title":"Glioma"},{"@id":"https://cir.nii.ac.jp/all?q=Injections,%20Intralesional","dc:title":"Injections, Intralesional"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Cancer%20Vaccines","dc:title":"Cancer Vaccines"},{"@id":"https://cir.nii.ac.jp/all?q=Immunotherapy,%20Adoptive","dc:title":"Immunotherapy, Adoptive"},{"@id":"https://cir.nii.ac.jp/all?q=Magnetic%20Resonance%20Imaging","dc:title":"Magnetic Resonance Imaging"},{"@id":"https://cir.nii.ac.jp/all?q=Survival%20Rate","dc:title":"Survival Rate"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Neoplasm%20Recurrence,%20Local","dc:title":"Neoplasm Recurrence, Local"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231194416000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283689744407552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Adoptive Cell Transfer Therapy For Malignant Gliomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714668545280","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866843823488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165279587584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK‐432 for resectable pancreatic cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565166034480000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cell- and peptide-based immunotherapeutic approaches for glioma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189269843072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576966732719232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Peptide Vaccine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640277513088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dendritic-cell- and peptide-based vaccination strategies for glioma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656124765312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680193851136","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Differential Induction from X-irradiated Human Peripheral Blood Monocytes to Dendritic Cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1520854805180018560","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"Phase Ⅰ trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650497350528","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600507054336","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975327771776","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Personalized peptide vaccines : A new therapeutic modality for cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1158/1078-0432.ccr-05-0120"},{"@type":"CIA","@value":"30018691145"},{"@type":"OPENAIRE","@value":"doi_dedup___::4c81fb3cfae0214e0fdfb37ab777e49c"},{"@type":"CROSSREF","@value":"10.1007/s00262-015-1674-8_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.3892/mmr.2015.3685_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/978-1-4614-3146-6_9_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/s00262-023-03482-8_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/s00534-011-0457-7_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.3171/2015.1.jns141554_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/978-1-4614-3146-6_13_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/s10143-009-0189-1_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1269/jrr.07122_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1007/s00262-018-2274-1_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"},{"@type":"CROSSREF","@value":"10.1016/j.molmed.2008.03.003_references_DOI_D3C1EHohTlwkrKD2mx0i3pe3VWB"}]}